RM 853

Drug Profile

RM 853

Alternative Names: RM-853; T-3525770

Latest Information Update: 09 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Takeda
  • Developer Rhythm; Takeda
  • Class Obesity therapies
  • Mechanism of Action Ghrelin O-acyltransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Prader-Willi syndrome

Most Recent Events

  • 02 Apr 2018 RM 853 licensed to Rhythm Pharmaceuticals worldwide
  • 02 Apr 2018 Preclinical trials in Prader-Willi syndrome in USA (PO) (before April 2018)
  • 02 Apr 2018 Rhythm Pharmaceuticals plans to file an IND application with the US FDA in USA for Prader-Willi syndrome in first quarter of 2020
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top